Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Constipation-Pipeline Review, H1 2015

Constipation-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Constipation-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Constipation-Pipeline Review, H1 2015', provides an overview of the Constipation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Constipation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Constipation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Constipation

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Constipation and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Constipation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Constipation pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Constipation

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Constipation pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Constipation Overview 8

Therapeutics Development 9

Pipeline Products for Constipation-Overview 9

Pipeline Products for Constipation-Comparative Analysis 10

Constipation-Therapeutics under Development by Companies 11

Constipation-Therapeutics under Investigation by Universities/Institutes 13

Constipation-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Unknown Stage Products 17

Constipation-Products under Development by Companies 18

Constipation-Products under Investigation by Universities/Institutes 19

Constipation-Companies Involved in Therapeutics Development 20

AlbireoPharma 20

Astellas Pharma Inc. 21

AstraZeneca PLC 22

Beech Tree Labs, Inc. 23

Braintree Laboratories, Inc. 24

Daiichi Sankyo Company, Limited 25

Dong-A Socio Group 26

Ironwood Pharmaceuticals, Inc. 27

Kissei Pharmaceutical Co., Ltd. 28

Lipid Pharmaceuticals ehf. 29

Rhythm Pharmaceuticals 30

Sanwa Kagaku Kenkyusho Co., Ltd. 31

Shire Plc 32

SK Biopharmaceuticals Co., Ltd. 33

Sucampo Pharmaceuticals, Inc. 34

Sumitomo Dainippon Pharma Co., Ltd. 35

Synergy Pharmaceuticals, Inc. 36

Teva Pharmaceutical Industries Limited 37

Constipation-Therapeutics Assessment 38

Assessment by Monotherapy Products 38

Assessment by Target 39

Assessment by Mechanism of Action 41

Assessment by Route of Administration 43

Assessment by Molecule Type 45

Drug Profiles 47

5-BOIP-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

ASP-7663-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

BLI-801-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

DA-6886-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

DS-3801-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

DSP-6952-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

elobixibat-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

KWA-0711-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

linaclotide-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

LP-101-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

lubiprostone-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

MDT-006-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

plecanatide-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

prucalopride succinate-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

relamorelin-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

SK-1202-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Small Molecule for Chronic Constipation-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

tenapanor hydrochloride-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Transilon-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

YKP-10811-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

Constipation-Recent Pipeline Updates 76

Constipation-Dormant Projects 97

Constipation-Product Development Milestones 98

Featured News & Press Releases 98

Nov 20, 2014: Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan 98

Nov 12, 2014: Sucampo Files Patent Infringement Lawsuit Against Dr. Reddy's 98

Nov 04, 2014: Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation 99

Oct 24, 2014: Rhythm Presents Positive Phase 2 Study Results for Relamorelin for Chronic Constipation 99

Oct 13, 2014: Clinical Data for AMITIZA Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting 101

Oct 09, 2014: Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA 102

Sep 18, 2014: Synergy Pharmaceuticals Reaches Halfway Mark for Second Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation 103

Aug 21, 2014: Sucampo Announces New Exclusive Global Manufacturing and Supply Agreement for Lubiprostone 103

Jul 14, 2014: Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation 104

May 06, 2014: Rhythm Presents Positive GI Motility Results for Relamorelin (RM-131) in Phase 2 Chronic Constipation Study 104

Appendix 106

Methodology 106

Coverage 106

Secondary Research 106

Primary Research 106

Expert Panel Validation 106

Contact Us 107

Disclaimer 107

List of Tables

Number of Products under Development for Constipation, H1 2015 9

Number of Products under Development for Constipation-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Comparative Analysis by Unknown Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Investigation by Universities/Institutes, H1 2015 19

Constipation-Pipeline by AlbireoPharma, H1 2015 20

Constipation-Pipeline by Astellas Pharma Inc., H1 2015 21

Constipation-Pipeline by AstraZeneca PLC, H1 2015 22

Constipation-Pipeline by Beech Tree Labs, Inc., H1 2015 23

Constipation-Pipeline by Braintree Laboratories, Inc., H1 2015 24

Constipation-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 25

Constipation-Pipeline by Dong-A Socio Group, H1 2015 26

Constipation-Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 27

Constipation-Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 28

Constipation-Pipeline by Lipid Pharmaceuticals ehf., H1 2015 29

Constipation-Pipeline by Rhythm Pharmaceuticals, H1 2015 30

Constipation-Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2015 31

Constipation-Pipeline by Shire Plc, H1 2015 32

Constipation-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 33

Constipation-Pipeline by Sucampo Pharmaceuticals, Inc., H1 2015 34

Constipation-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 35

Constipation-Pipeline by Synergy Pharmaceuticals, Inc., H1 2015 36

Constipation-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 37

Assessment by Monotherapy Products, H1 2015 38

Number of Products by Stage and Target, H1 2015 40

Number of Products by Stage and Mechanism of Action, H1 2015 42

Number of Products by Stage and Route of Administration, H1 2015 44

Number of Products by Stage and Molecule Type, H1 2015 46

Constipation Therapeutics-Recent Pipeline Updates, H1 2015 76

Constipation-Dormant Projects, H1 2015 97

List of Figures

Number of Products under Development for Constipation, H1 2015 9

Number of Products under Development for Constipation-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 38

Number of Products by Top 10 Targets, H1 2015 39

Number of Products by Stage and Top 10 Targets, H1 2015 40

Number of Products by Top 10 Mechanism of Actions, H1 2015 41

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 42

Number of Products by Top 10 Routes of Administration, H1 2015 43

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 44

Number of Products by Top 10 Molecule Types, H1 2015 45

Number of Products by Stage and Top 10 Molecule Types, H1 2015 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AlbireoPharma

Astellas Pharma Inc.

AstraZeneca PLC

Beech Tree Labs, Inc.

Braintree Laboratories, Inc.

Daiichi Sankyo Company, Limited

Dong-A Socio Group

Ironwood Pharmaceuticals, Inc.

Kissei Pharmaceutical Co., Ltd.

Lipid Pharmaceuticals ehf.

Rhythm Pharmaceuticals

Sanwa Kagaku Kenkyusho Co., Ltd.

Shire Plc

SK Biopharmaceuticals Co., Ltd.

Sucampo Pharmaceuticals, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Synergy Pharmaceuticals, Inc.

Teva Pharmaceutical Industries Limited

Constipation Therapeutic Products under Development, Key Players in Constipation Therapeutics, Constipation Pipeline Overview, Constipation Pipeline, Constipation Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com